ID   LEC_CREGR               Reviewed;         150 AA.
AC   H2FH31;
DT   29-SEP-2021, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2012, sequence version 1.
DT   03-AUG-2022, entry version 25.
DE   RecName: Full=Galactose-binding lectin {ECO:0000303|PubMed:27010847, ECO:0000303|PubMed:28740170};
DE   AltName: Full=CGL {ECO:0000303|PubMed:26527272, ECO:0000303|PubMed:27010847, ECO:0000303|PubMed:28636877, ECO:0000303|PubMed:28740170, ECO:0000303|PubMed:30486373, ECO:0000303|PubMed:31905927, ECO:0000303|Ref.3};
DE   AltName: Full=GalNAc/Gal-specific lectin {ECO:0000303|PubMed:23886951, ECO:0000303|PubMed:25482060, ECO:0000303|PubMed:26439416, ECO:0000303|PubMed:28740170, ECO:0000303|PubMed:30486373, ECO:0000303|PubMed:31905927, ECO:0000303|PubMed:9568372};
OS   Crenomytilus grayanus (Gray mussel) (Mytilus grayanus).
OC   Eukaryota; Metazoa; Spiralia; Lophotrochozoa; Mollusca; Bivalvia;
OC   Autobranchia; Pteriomorphia; Mytilida; Mytiloidea; Mytilidae; Mytilinae;
OC   Crenomytilus.
OX   NCBI_TaxID=151218;
RN   [1] {ECO:0000312|EMBL:AEY80387.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 14-20; 30-50; 68-84;
RP   88-102; 106-110 AND 129-140, FUNCTION, ACTIVITY REGULATION, CIRCULAR
RP   DICHROISM ANALYSIS, AND PHYLOGENETIC ANALYSIS.
RX   PubMed=23886951; DOI=10.1016/j.fsi.2013.07.011;
RA   Kovalchuk S.N., Chikalovets I.V., Chernikov O.V., Molchanova V.I., Li W.,
RA   Rasskazov V.A., Lukyanov P.A.;
RT   "cDNA cloning and structural characterization of a lectin from the mussel
RT   Crenomytilus grayanus with a unique amino acid sequence and antibacterial
RT   activity.";
RL   Fish Shellfish Immunol. 35:1320-1324(2013).
RN   [2]
RP   FUNCTION, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9568372; DOI=10.1016/s0742-8413(97)00180-1;
RA   Belogortseva N.I., Molchanova V.I., Kurika A.V., Skobun A.S.,
RA   Glazkova V.E.;
RT   "Isolation and characterization of new GalNAc/Gal-specific lectin from the
RT   sea mussel Crenomytilus grayanus.";
RL   Comp. Biochem. Physiol. 119C:45-50(1998).
RN   [3]
RP   FUNCTION, ACTIVITY REGULATION, SUBUNIT, AND DOMAIN.
RA   Chikalovets I.V., Molchanova V.I., Chernikov O.V., Lukyanov P.A.;
RT   "Domain organization of lectin from the mussel Crenomytilus grayanus.";
RL   Chem. Nat. Comp. 50:706-709(2014).
RN   [4]
RP   FUNCTION, ACTIVITY REGULATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=25482060; DOI=10.1016/j.fsi.2014.11.036;
RA   Chikalovets I.V., Chernikov O.V., Pivkin M.V., Molchanova V.I.,
RA   Litovchenko A.P., Li W., Lukyanov P.A.;
RT   "A lectin with antifungal activity from the mussel Crenomytilus grayanus.";
RL   Fish Shellfish Immunol. 42:503-507(2015).
RN   [5]
RP   FUNCTION, ACTIVITY REGULATION, MUTAGENESIS OF HIS-16; PRO-17; GLY-19;
RP   HIS-64; PRO-65; GLY-67; HIS-108; PRO-109 AND GLY-111, AND 3D-STRUCTURE
RP   MODELING.
RX   PubMed=26439416; DOI=10.1016/j.fsi.2015.09.045;
RA   Kovalchuk S.N., Golotin V.A., Balabanova L.A., Buinovskaya N.S.,
RA   Likhatskaya G.N., Rasskazov V.A.;
RT   "Carbohydrate-binding motifs in a novel type lectin from the sea mussel
RT   Crenomytilus grayanus: Homology modeling study and site-specific
RT   mutagenesis.";
RL   Fish Shellfish Immunol. 47:565-571(2015).
RN   [6]
RP   FUNCTION, ACTIVITY REGULATION, AND BIOTECHNOLOGY.
RX   PubMed=28636877; DOI=10.1016/j.ijbiomac.2017.06.074;
RA   Chernikov O., Kuzmich A., Chikalovets I., Molchanova V., Hua K.F.;
RT   "Lectin CGL from the sea mussel Crenomytilus grayanus induces Burkitt's
RT   lymphoma cells death via interaction with surface glycan.";
RL   Int. J. Biol. Macromol. 104:508-514(2017).
RN   [7]
RP   FUNCTION, AND BIOTECHNOLOGY.
RX   PubMed=28740170; DOI=10.1038/s41598-017-06647-5;
RA   Chernikov O.V., Wong W.T., Li L.H., Chikalovets I.V., Molchanova V.I.,
RA   Wu S.H., Liao J.H., Hua K.F.;
RT   "A GalNAc/Gal-specific lectin from the sea mussel Crenomytilus grayanus
RT   modulates immune response in macrophages and in mice.";
RL   Sci. Rep. 7:6315-6315(2017).
RN   [8]
RP   FUNCTION, BIOTECHNOLOGY, MUTAGENESIS OF ASN-27; HIS-37; GLU-75; HIS-85;
RP   ASN-119; ASP-127 AND HIS-129, IN SILICO ANALYSIS OF BINDING TO GALACTOSE;
RP   GLOBOTRIOSE GB3 AND PORCINE STOMACH MUCIN TRISACCHARIDE, AND 3D-STRUCTURE
RP   MODELING OF THE LIGAND BINDING SITE IN COMPLEX WITH GLOBOTRIOSE GB3 AND
RP   PORCINE STOMACH MUCIN TRISACCHARIDE.
RX   PubMed=30486373; DOI=10.3390/md16120471;
RA   Kovalchuk S.N., Buinovskaya N.S., Likhatskaya G.N., Rasskazov V.A.,
RA   Son O.M., Tekutyeva L.A., Balabanova L.A.;
RT   "Mutagenesis Studies and Structure-function Relationships for GalNAc/Gal-
RT   Specific Lectin from the Sea Mussel Crenomytilus grayanus.";
RL   Mar. Drugs 16:0-0(2018).
RN   [9]
RP   FUNCTION, BIOTECHNOLOGY, AND REVIEW.
RX   PubMed=31905927; DOI=10.3390/molecules25010150;
RA   Chikalovets I., Filshtein A., Molchanova V., Mizgina T., Lukyanov P.,
RA   Nedashkovskaya O., Hua K.F., Chernikov O.;
RT   "Activity Dependence of a Novel Lectin Family on Structure and
RT   Carbohydrate-Binding Properties.";
RL   Molecules 25:0-0(2019).
RN   [10] {ECO:0007744|PDB:5DUY}
RP   X-RAY CRYSTALLOGRAPHY (2.12 ANGSTROMS), AND SUBUNIT.
RX   PubMed=26527272; DOI=10.1107/s2053230x15019858;
RA   Jakob M., Lubkowski J., O'Keefe B.R., Wlodawer A.;
RT   "Structure of a lectin from the sea mussel Crenomytilus grayanus (CGL).";
RL   Acta Crystallogr. F Struct. Biol. Commun. 71:1429-1436(2015).
RN   [11] {ECO:0007744|PDB:5F8S, ECO:0007744|PDB:5F8W, ECO:0007744|PDB:5F8Y, ECO:0007744|PDB:5F90}
RP   X-RAY CRYSTALLOGRAPHY (1.08 ANGSTROMS) AND IN COMPLEX WITH GALACTOSE;
RP   GALACTOSAMINE AND GLOBOTRIOSE GB3, FUNCTION, SUBUNIT, BIOTECHNOLOGY, NMR
RP   SPECTROSCOPY, AND PHYLOGENETIC ANALYSIS.
RX   PubMed=27010847; DOI=10.1021/jacs.6b00111;
RA   Liao J.H., Chien C.T., Wu H.Y., Huang K.F., Wang I., Ho M.R., Tu I.F.,
RA   Lee I.M., Li W., Shih Y.L., Wu C.Y., Lukyanov P.A., Hsu S.T., Wu S.H.;
RT   "A Multivalent Marine Lectin from Crenomytilus grayanus Possesses Anti-
RT   cancer Activity through Recognizing Globotriose Gb3.";
RL   J. Am. Chem. Soc. 138:4787-4795(2016).
CC   -!- FUNCTION: Galactose-binding lectin (PubMed:23886951, PubMed:27010847,
CC       PubMed:9568372, PubMed:28636877). Binds both alpha and beta anomer of
CC       galactose (Gal), but has a stronger interaction with the glycans having
CC       alpha Gal at the non-reducing end and binds beta Gal weakly only in
CC       highly branched glycans. Has high affinity to Galalpha1-4Galbeta1-
CC       4GlcNAc (PubMed:28636877). Binds N-acetyl-2-deoxy-2-amino-galactose (2-
CC       deoxy-GalNAc) (PubMed:23886951, PubMed:9568372). Binds N-
CC       acetylgalactosamine (GalNAc) (PubMed:26439416). Binds porcine stomach
CC       mucin (PSM) with high affinity (PubMed:26439416, PubMed:30486373).
CC       Binds galactosamine (PubMed:27010847). Binds laminin, bovine
CC       submaxillary mucin (BSM), fibronectin, type I collagen and gelatin with
CC       a decreasing affinity, respectively (Ref.3). Has hemagglutinating
CC       activity towards human type A erythrocytes (PubMed:9568372,
CC       PubMed:26439416, Ref.3). Hemagglutinates also human type 0, B and AB
CC       erythrocytes as well as rabbit and mouse erythrocytes (PubMed:9568372).
CC       Agglutinates both Gram-positive and Gram-negative bacteria including
CC       B.subtilis ATCC 6633, S.aureus ATCC 21027 and E.coli 3254,
CC       respectively. No agglutination activity towards Gram-positive
CC       S.amurskyense CMM 3673. Has bacteriostatic activity on S.amurskyense
CC       CMM 3673, B.subtilis ATCC 6633, S.aureus ATCC 21027 and E.coli 3254.
CC       However, has no agglutination nor bacteriostatic activity on Gram-
CC       negative C.scophthalmum CIP 104199 or A.troitsensis KMM 3674
CC       (PubMed:23886951). Inhibits growth of fungi from the genera
CC       Aspergillus, Penicillium, Trichoderma and st. Mycelia. Inhibits
CC       germination of spores and hyphal growth of them (PubMed:25482060). Has
CC       dose-dependent cytotoxic effect on the human globotriaosylceramide
CC       (Gb3)-expressing Burkitt's lymphoma (Raji) cell line. Binds to Gb3 in
CC       these cells leading to activation of caspase-9/3 and PARP
CC       (PubMed:28636877). Has dose-dependent cytotoxic effect on the Gb3-
CC       expressing human MCF-7 breast cancer cell line (PubMed:27010847). No
CC       cytotoxic effect on myelogenous leukemia K562 cell line, which does not
CC       express Gb3 (PubMed:28636877). Activates immune responses in mice and
CC       increases cytokine production of TNF-alpha, IL-6 and MCP-1 in the serum
CC       and the peritoneal lavage of mice. Induces TNF-alpha and IL-6 secretion
CC       in mouse RAW264.7 macrophages, mouse bone marrow-derived macrophages,
CC       human THP-1 macrophages, human peripheral blood mononuclear cells
CC       (PBMCs) and human blood monocyte-derived macrophages. TNF-alpha
CC       production in macrophages could not be inhibited by GalNAc, GalN or
CC       Gal, indicating that induced cytokine production is separate from its
CC       sugar binding activity. Increases intracellular reactive oxygen species
CC       levels, expression and phosphorylation of protein kinases PKC
CC       alpha/delta, expression of COX-2 and NF-kappaB, and activates the MAPK
CC       pathway by increasing the phosphorylation of ERK1/2, JNK1/2 and p38 in
CC       mouse RAW264.7 macrophages. Induces endotoxin tolerance in
CC       lipopolysaccharide(LPS)-activated macrophages by down-regulating IRAK2
CC       expression, reducing JNK1/2 phosphorylation and NF-kappaB activation.
CC       Can slightly increase the bactericidal activity of RAW264.7 macrophages
CC       (PubMed:28740170). Has DNA-binding activity (PubMed:27010847).
CC       Recognizes pathogen-associated molecular patterns (PAMPs) and binds to
CC       LPS from E.coli, but has only little binding to beta-1,3-glucan from
CC       E.gracilis and peptidoglycan from S.aureus. Activates secretion of TNF-
CC       alpha and IFN-gamma by the human peripheral blood cells (HPBCs)
CC       (PubMed:31905927). May be involved in innate immunity acting as an
CC       antibacterial and antifungal agent involved in the recognition and
CC       clearance of pathogens (PubMed:23886951, PubMed:25482060,
CC       PubMed:31905927). {ECO:0000269|PubMed:23886951,
CC       ECO:0000269|PubMed:25482060, ECO:0000269|PubMed:26439416,
CC       ECO:0000269|PubMed:27010847, ECO:0000269|PubMed:28636877,
CC       ECO:0000269|PubMed:28740170, ECO:0000269|PubMed:30486373,
CC       ECO:0000269|PubMed:31905927, ECO:0000269|PubMed:9568372,
CC       ECO:0000269|Ref.3}.
CC   -!- ACTIVITY REGULATION: Bacterial binding activity is inhibited by D-
CC       galactose (PubMed:23886951). Hemagglutinating activity is independent
CC       of divalent cations Ca2(+) or Mg2(+). It is strongly inhibited by N-
CC       acetyl-D-galactosamine (GalNAc), D-galactose and D-talose, and to a
CC       lesser extent by melibiose and raffinose. Also inhibited by
CC       glycoprotein asialo-bovine submaxillary mucin (BSM). Not inhibited by
CC       D-glucose, D-fucose, D-galactitol, N-acetyl-D-glucosamine or lactose
CC       (PubMed:9568372, PubMed:26439416). Fungal binding activity is inhibited
CC       by D-galactose (PubMed:25482060). Cytotoxic activity against Raji cell
CC       line is completely inhibited by galactose, melibiose and raffinose, but
CC       not by glucose or lactose (PubMed:28636877). Galactose inhibits binding
CC       to laminin and BSM, but not to collagen, gelatin or fibronectin
CC       (Ref.3). {ECO:0000269|PubMed:23886951, ECO:0000269|PubMed:25482060,
CC       ECO:0000269|PubMed:26439416, ECO:0000269|PubMed:28636877,
CC       ECO:0000269|PubMed:9568372, ECO:0000269|Ref.3}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is between 8-10 for the hemagglutinating activity of the
CC         human erythrocytes. {ECO:0000269|PubMed:9568372};
CC       Temperature dependence:
CC         Hemagglutinating activity of the human erythrocytes is fully
CC         maintained after heating at 50 degrees Celsius for 3 hours. The
CC         activity is partially lost after heating at 55 degrees Celsius and
CC         completely lost after heating at 65 degrees Celsius for 30 minutes.
CC         {ECO:0000269|PubMed:9568372};
CC   -!- SUBUNIT: Monomer in solution (PubMed:26527272). Homodimer in solution
CC       (PubMed:27010847). Exists as a monomer in solution when a low
CC       concentration (0.001 mg/ml) of it is present. Homodimers start to
CC       appear at a concentration of 0.01 mg/ml and tetramers at a
CC       concentration of 0.1 mg/ml (Ref.3). {ECO:0000269|PubMed:26527272,
CC       ECO:0000269|PubMed:27010847, ECO:0000269|Ref.3}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in mantle and to a lesser extent
CC       in muscle, hepatopancreas, gill and hemocytes.
CC       {ECO:0000269|PubMed:25482060}.
CC   -!- INDUCTION: Up-regulated in mantle by challenge of yeast P.pastoris
CC       reaching the maximum level at 12 hours post challenge and recovering to
CC       the original level at 24 hours post challenge.
CC       {ECO:0000269|PubMed:25482060}.
CC   -!- DOMAIN: Contains a collagen like domain, which probably promotes
CC       oligomerization. {ECO:0000269|Ref.3}.
CC   -!- BIOTECHNOLOGY: This protein may have potential in cancer diagnosis and
CC       treatment (PubMed:28636877, PubMed:27010847, PubMed:30486373,
CC       PubMed:31905927). A synthetic analog of this protein with enhanced
CC       carbohydrate-binding properties may be designed for the purpose of
CC       constructing a biosensor for cancer diagnostics or anticancer therapy
CC       (PubMed:30486373). May potentially be used as an immune modulator in
CC       mammals, because of its effects on macrophages and its ability to
CC       promote secretion of cytokines (PubMed:28740170).
CC       {ECO:0000305|PubMed:27010847, ECO:0000305|PubMed:28636877,
CC       ECO:0000305|PubMed:28740170, ECO:0000305|PubMed:30486373,
CC       ECO:0000305|PubMed:31905927}.
CC   -!- MISCELLANEOUS: Cleavage of the collagen like domain may decrease the
CC       agglutinating ability and alter carbohydrate-binding properties. The
CC       function of this protein could potentially be regulated by proteolysis
CC       in vivo. {ECO:0000305|Ref.3}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JQ314213; AEY80387.1; -; mRNA.
DR   PDB; 5DUY; X-ray; 2.12 A; A/B/C/D/E/F=1-150.
DR   PDB; 5F8S; X-ray; 1.08 A; A/B=1-150.
DR   PDB; 5F8W; X-ray; 1.56 A; A/B=1-150.
DR   PDB; 5F8Y; X-ray; 1.70 A; A/B=1-150.
DR   PDB; 5F90; X-ray; 1.64 A; A/B=1-150.
DR   PDBsum; 5DUY; -.
DR   PDBsum; 5F8S; -.
DR   PDBsum; 5F8W; -.
DR   PDBsum; 5F8Y; -.
DR   PDBsum; 5F90; -.
DR   SMR; H2FH31; -.
DR   UniLectin; H2FH31; -.
DR   PRIDE; H2FH31; -.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Glycoprotein; Hemagglutinin;
KW   Lectin.
FT   CHAIN           1..150
FT                   /note="Galactose-binding lectin"
FT                   /id="PRO_0000453467"
FT   BINDING         16
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         19
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         27
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F90"
FT   BINDING         35..37
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         64
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         67
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         75
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         83..85
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         108
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   BINDING         111
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0007744|PDB:5F8W"
FT   BINDING         119
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F90"
FT   BINDING         127..129
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:27010847,
FT                   ECO:0007744|PDB:5F8W"
FT   CARBOHYD        26
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        74
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        118
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   MUTAGEN         16
FT                   /note="H->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-17 and
FT                   A-19."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         17
FT                   /note="P->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-16 and
FT                   A-19."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         19
FT                   /note="G->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-16 and
FT                   A-17."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         27
FT                   /note="N->A: 5.9-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         37
FT                   /note="H->A: 1.4-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         64
FT                   /note="H->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-65 and
FT                   A-67."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         65
FT                   /note="P->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-64 and
FT                   A-67."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         67
FT                   /note="G->A: Loss of hemagglutinating and porcine stomach
FT                   mucin-binding activities; when associated with A-64 and
FT                   A-65."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         75
FT                   /note="E->A: 3.2-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         85
FT                   /note="H->A: 5.0-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         108
FT                   /note="H->A: Retains slight hemagglutinating activity and
FT                   has 6-fold decreased porcine stomach mucin-binding
FT                   activity; when associated with A-109 and A-111."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         109
FT                   /note="P->A: Retains slight hemagglutinating activity and
FT                   has 6-fold decreased porcine stomach mucin-binding
FT                   activity; when associated with A-108 and A-111."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         111
FT                   /note="G->A: Retains slight hemagglutinating activity and
FT                   has 6-fold decreased porcine stomach mucin-binding
FT                   activity; when associated with A-108 and A-109."
FT                   /evidence="ECO:0000269|PubMed:26439416"
FT   MUTAGEN         119
FT                   /note="N->A: 11.1-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         127
FT                   /note="D->A: 4.5-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   MUTAGEN         129
FT                   /note="H->A: 2.3-fold decreased porcine stomach
FT                   mucin-binding activity compared to wild-type."
FT                   /evidence="ECO:0000269|PubMed:30486373"
FT   STRAND          4..8
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   TURN            9..11
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          14..17
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          28..34
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   HELIX           38..40
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          42..48
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          51..56
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   TURN            57..59
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          62..65
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          77..82
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          90..93
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   TURN            94..97
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          98..101
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          106..109
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          120..125
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   HELIX           130..132
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          134..138
FT                   /evidence="ECO:0007829|PDB:5F8S"
FT   STRAND          141..145
FT                   /evidence="ECO:0007829|PDB:5F8S"
SQ   SEQUENCE   150 AA;  17023 MW;  9DA43920298898C9 CRC64;
     MTTFLIKHKA SGKFLHPYGG SSNPANNTKL VLHSDIHERM YFQFDVVDER WGYIKHVASG
     KIVHPYGGQA NPPNETNMVL HQDRHDRALF AMDFFNDNIM HKGGKYIHPK GGSPNPPNNT
     ETVIHGDKHA AMEFIFVSPK NKDKRVLVYA
//
